The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 4: 459 - 464

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.04.001

Guidelines Interpretation

Interpretation of ACG clinical practice guideline in 2024： treatment of helicobacter pylori infection

  • Xinguo WU ,
  • Ruhua ZHENG ,
  • Xin CHANG ,
  • Chunyan NIU ,
  • Fuyu. ZHANG
Expand
  • Department of Gastroenterology，Nanjing Lishui People′s Hospital，Nanjing 211200，Jiangsu，China

Received date: 2024-11-21

  Online published: 2025-02-28

Fold

Abstract

Helicobacter pylori （H.pylori） infection is a prevalent global health issue that can lead to indigestion， peptic ulcer disease， and gastric cancer. With ongoing research advancements， significant progress has been made in the eradication of H.pylori. Based on these important findings from North America， the American College of Gastroenterology （ACG） has released updated clinical practice guideline （CPG）， published in the American Journal of Gastroenterology in September 2024. Compared to previous guidelines， key updates include： increased resistance rates to critical antibiotics used for H.pylori treatment， such as clarithromycin and levofloxacin， which have reduced the efficacy of common treatment regimens containing these antibiotics； and research on novel treatment options for newly diagnosed patients， including new antibiotic alternatives （e.g.， rifampicin） or more potent next?generation gastric acid inhibitors （e.g.， potassium?competitive acid blockers， PCABs）. These updates provide the latest evidence and reference for the clinical management of H.pylori infection.

Key words： helicobacter pylori; infection; management; the American College of Gastroenterology; clinical practice guideline

Cite this article

Xinguo WU , Ruhua ZHENG , Xin CHANG , Chunyan NIU , Fuyu. ZHANG . Interpretation of ACG clinical practice guideline in 2024： treatment of helicobacter pylori infection[J]. The Journal of Practical Medicine, 2025 , 41(4) : 459 -464 . DOI: 10.3969/j.issn.1006-5725.2025.04.001

References

1 DE MARTEL C， GEORGES D， BRAY F， et al. Global burden of cancer attributable to infections in 2018： A worldwide incidence analysis［J］. Lancet Glob Health， 2020， 8（2）：e180-190. doi:10.1016/s2214-109x(19)30488-7
2 PENNELLI G， GRILLO F， GALUPPINI F， et al. Gastritis： Update on etiological features and histological practical approach［J］. Pathologica， 2020， 112（3）： 153-165. doi:10.32074/1591-951x-163
3 CHEY W D， HOWDEN C W， MOSS S F， et al. ACG Clinical Guideline： Treatment of Helicobacter pylori Infection［J］.Am J Gastroenterol， 2024， 119（9）：1730-1753. doi:10.14309/ajg.0000000000002968
4 LI Y， CHOI H， LEUNG K， et al. Global prevalence of Helicobacter pylori infection between 1980 and 2022： A systematic review and meta analysis［J］. Lancet Gastroenterol Hepatol， 2023， 8（6）：553-564. doi:10.1016/s2468-1253(23)00070-5
5 CHEN Y C， MALFERTHEINER P， YU H T， et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022［J］. Gastroenterology， 2024， 166（4）：605-619. doi:10.1053/j.gastro.2023.12.022
6 MALFERTHEINER P， CAMARGO M C， EL-OMAR E， et al. Helicobacter pylori infection［J］. Nat Rev Dis Primers， 2023， 9（1）：19. doi:10.1038/s41572-023-00431-8
7 WECHSLER E V， AHUJA N K， BRENNER D， et al. Up-Front Endoscopy Maximizes Cost-Effectiveness and Cost-Satisfaction in Uninvestigated Dyspepsia［J］. Clin Gastroenterol Hepatol， 2023， 21（9）：2378-2388.e28. doi:10.1016/j.cgh.2023.01.003
8 SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin， 2021， 71（3）：209-249. doi:10.3322/caac.21660
9 ALLEMANI C， MATSUDA T， DI CARLO V， et al. Global surveillance of trends in cancer survival 2000-14 （CONCORD-3）： Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries［J］. Lancet， 2018， 391（10125）： 1023-1075. doi:10.1016/S0140-6736(17)33326-3
10 CHIANG T H， CHANG W J， CHEN S L， et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality： A long-term cohort study on Matsu Islands［J］. Gut， 2021， 70（2）：243-250.
11 RUGGE M， BRICCA L， GUZZINATI S， et al. Autoimmune gastritis： Long-term natural history in naive Helicobacter pylori-negative patients［J］. Gut， 2023， 72（1）：30-38. doi:10.1136/gutjnl-2022-327827
12 SAVOLDI A， CARRARA E， GRAHAM D Y， et al. Prevalence of antibiotic resistance in Helicobacter pylori： A systematic review and meta-analysis in World Health Organization regions［J］. Gastroenterology， 2018， 155（5）： 1372-1382.e17. doi:10.1053/j.gastro.2018.07.007
13 HO J J C， NAVARRO M， SAWYER K， et al. Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021： A systematic review and meta-analysis［J］. Am J Gastroenterol， 2022， 117（8）：1221-1230. doi:10.14309/ajg.0000000000001828
14 ZANICHELLI V， SHARLAND M， CAPPELLO B， et al. The WHO AWaRe （Access， Watch， Reserve） antibiotic book and prevention of antimicrobial resistance［J］. Bull World Health Organ， 2023， 101（4）：290-296. doi:10.2471/blt.22.288614
15 FERNANDEZ-CASO B， MIQUELEIZ A， ALARCON T. Whole genome sequencing for studying Helicobacter pylori antimicrobial resistance［J］. Antibiotics （Basel）， 2023， 12（7）：1135. doi:10.3390/antibiotics12071135
16 TANAKA S， GOTO A， YAMAGISHI K， et al. Long-term Response of Helicobacter pylori Antibody Titer After Eradication Treatment in Middle-aged Japanese： JPHC-NEXT Study［J］. J Epidemiol， 2023， 33（1）：1-7. doi:10.2188/jea.je20200618
17 HONG T C， EL-OMAR E M， KUO Y T， et al. Asian Pacific Alliance on Helicobacter and Microbiota. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022： An updated systematic review and meta-analysis［J］. Lancet Gastroenterol Hepatol， 2024， 9（1）：56-67. doi:10.1016/s2468-1253(23)00281-9
18 RAUT S， ADHIKARI B. Global leadership against antimicrobial resistance ought to include developing countries［J］. Lancet Infect Dis， 2016， 16（7）：775. doi:10.1016/s1473-3099(16)30078-0
19 ZAGARI R M， DAJTI E， COMINARDI A， et al. Standard bismuth quadruple therapy versus concomitant therapy for the first-line treatment of Helicobacter pylori infection： A systematic review and meta-analysis of randomized controlled trials［J］. J Clin Med， 2023， 12（9）：3258. doi:10.3390/jcm12093258
20 GRAHAM D Y， CANAAN Y， MAHER J， et al. Rifabutin-based triple therapy （RHB-105） for Helicobacter pylori eradication： A double-blind， randomized， controlled trial［J］. Ann Intern Med， 2020， 172（12）：795-802. doi:10.7326/m19-3734
21 LAINE L， SHARMA P， MULFORD D J， et al. Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects［J］. Am J Gastroenterol， 2022， 117（7）：1158-1161. doi:10.14309/ajg.0000000000001735
22 PATEL A， LAINE L， MOAYYEDI P， et al. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice： Expert Review［J］. Gastroenterology， 2024， 167（6）：1228-1238. doi:10.1053/j.gastro.2024.06.038
23 YAN T L， WANG J H， HE X J， et al. Ten-day vonoprazan-amoxicillin dual therapy vs standard 14-day bismuth-based quadruple therapy for firstline Helicobacter pylori eradication： A multicenter randomized clinical trial［J］. Am J Gastroenterol， 2024， 119（4）：655-661. doi:10.14309/ajg.0000000000002592
24 CHEY W D， MEGRAUD F， LAINE L， et al. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe： Randomized clinical trial［J］. Gastroenterology， 2022， 163（3）：608-619. doi:10.1053/j.gastro.2022.05.055
Options
Outlines

/

〈 〉